Evidence page · about 6 minutes
Semaglutide and tirzepatide: what the trials show
The two medicines most women ask about, side by side. Trial numbers, how strong each finding is, and what no trial has answered yet.
Reviewed by the Kenning clinical and outcomes research team · Updated November 2026
This page compares trial results. It doesn’t say which medicine is right for you. That depends on your health, your other medicines and your goals, so decide with your prescriber.
20.2% vs 13.7%
Average weight lost over 72 weeks on tirzepatide and on semaglutide, in the only head-to-head trial.
Aronne et al., SURMOUNT-5, NEJM 2025
The two medicines at a glance
Semaglutide
Tirzepatide
What it is
SemaglutideA GLP-1 medicine. It copies one gut hormone that tells the brain you are full.
TirzepatideA GIP and GLP-1 medicine. It copies two gut hormones.
Brand names
SemaglutideWegovy (weight), Ozempic (diabetes)
TirzepatideMounjaro, Zepbound
How it’s taken
SemaglutideOnce a week by injection. A daily pill (Wegovy, 25 mg) was approved in the US in December 2025.
TirzepatideOnce a week by injection
Dose steps
SemaglutideStarts at 0.25 mg. Goes up every 4 weeks to 2.4 mg by week 16.
TirzepatideStarts at 2.5 mg. Goes up 2.5 mg every 4 weeks, to 5, 10 or 15 mg.
In Hong Kong
SemaglutideRegistered. Wegovy launched November 2025.
TirzepatideRegistered for weight and diabetes, October 2024.
Heart outcomes
SemaglutideLowered heart attack, stroke and heart death by 20% in people with heart disease and no diabetes (SELECT).
TirzepatideMatched an older GLP-1 in people with diabetes and heart disease. A trial in people without diabetes is still running.
Weight lost in the trials
Average percent of starting weight lost. Bars on the same card can be compared. Bars on different cards came from different trials.
Head to head: the only direct comparison
Open-label and funded by the maker of tirzepatide. Each person took the highest dose she could tolerate.
Each medicine against placebo, worldwide
Two separate trials. They were run at different times with different people, so read them side by side with care.
Trials in East Asian adults
Each trial compared one medicine with placebo. The China trial was shorter, at 52 weeks. Placebo results ranged from 1.7% to 2.3%.
Two rulers
Where the line sits for Asian women, and where it’s the same for everyone.
Who the trials let in
General line
BMI 30
or 27 with a weight-related condition (STEP 1, SURMOUNT-1, SURMOUNT-5)
Asian line
BMI 28
or 24 with a weight-related condition (SURMOUNT-CN). Hong Kong counts obesity from BMI 25.
Asian women carry more health risk at a lower BMI. The trials in East Asia were designed around that.
Percent of weight lost
Same line for everyone
East Asian trials found losses in the same range as global trials: 13.2% on semaglutide, and 17.5% to 22.7% on tirzepatide 15 mg.
Side effects and stopping
Same line for everyone
The Japan trial reported a safety profile consistent with global trials. Regain after stopping hasn’t been studied in Asian women separately.
Side effects
StrongMostly nausea, diarrhea, constipation and vomiting. Most were mild to moderate and happened while the dose was going up.
Semaglutide
Tirzepatide
Any stomach or gut side effect, head to head
79.0%
76.7%
Nausea, against placebo
44% vs 17% on placebo (STEP 1)
25% to 33%, by dose (SURMOUNT-1)
Stopped because of side effects, against placebo
7.0% vs 3.1% on placebo
4.3% to 7.1% vs 2.6% on placebo
Head-to-head rates come from SURMOUNT-5. The other rows come from separate placebo trials.
Muscle
MixedSemaglutide, STEP 1 scan study
Tirzepatide, SURMOUNT-1 scan study
Part of the weight lost on both medicines is lean mass, which includes muscle. The share looked smaller with tirzepatide, but the two scan studies were small and separate.
Check your Mirror FourStopping
StrongTwo-thirds
of the lost weight came back within a year of stopping semaglutide (STEP 1 extension)
In SURMOUNT-4, people who switched from tirzepatide to placebo regained 14% of their weight over a year. Those who stayed on it lost another 5.5%.
Make a stopping planMenopause hormone therapy
Early19.2% vs 14.0%
weight lost on tirzepatide with and without hormone therapy, in 120 women after menopause
A smaller study found the same pattern with semaglutide. These were record reviews, not trials, and most women were White. They can’t show that hormone therapy caused the extra loss.
GLP-1 and menopauseWhat the trials can’t tell you yet
- Which one will work better for you. Averages hide a wide spread. Some people lose much more than average and some much less.
- How Asian women in menopause do. No trial has reported results for this group on its own.
- Whether tirzepatide protects the heart in people without diabetes. That trial is still running.
- What happens after many years. Most trials ran 1 to 2 years.
Take to your appointment
Questions for your prescriber
- Given my health and other medicines, which would you choose for me, and why?
- What dose will I start on, and how fast will we go up?
- What should I do if the side effects are hard to manage?
- How will we protect my muscle while I lose weight?
- Does my menopause treatment change anything?
- If I stop one day, what’s our plan?
+ Where this comes from
- Aronne LJ, et al. Tirzepatide as compared with semaglutide for the treatment of obesity (SURMOUNT-5). NEJM, 2025.
- Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). NEJM, 2021.
- Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). NEJM, 2022.
- Kadowaki T, et al. Semaglutide in an East Asian population (STEP 6). Lancet Diabetes & Endocrinology, 2022.
- SURMOUNT-J: tirzepatide in Japanese adults with obesity disease. Lancet Diabetes & Endocrinology, 2025; trial registry results.
- Zhao L, et al. Tirzepatide in Chinese adults with obesity (SURMOUNT-CN). JAMA, 2024.
- Wilding JPH, et al. Weight regain after withdrawal of semaglutide: STEP 1 extension. Diabetes, Obesity and Metabolism, 2022.
- Aronne LJ, et al. Continued tirzepatide for maintenance of weight reduction (SURMOUNT-4). JAMA, 2024.
- Lincoff AM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT). NEJM, 2023.
- SURPASS-CVOT summary: tirzepatide vs dulaglutide in type 2 diabetes and heart disease. 2025.
- FDA approval of oral semaglutide 25 mg (Wegovy pill), OASIS 4. December 2025.
- Hurtado MD, et al. Menopausal hormone therapy and weight loss with semaglutide. Menopause, 2024.
- Castaneda R, et al. Hormone therapy and tirzepatide after menopause. Lancet Obstetrics, Gynaecology & Women’s Health, 2026.
- Hong Kong approval of tirzepatide, October 2024 and Wegovy launch in Hong Kong, November 2025.
- Nguyen N, Lu J. The Mirror and the Medicine. Kenning Health, 2027.
How we label strength: Strong means large randomized trials agree. Mixed means the studies point the same way but weren’t built to compare directly. Early means small or observational studies. Kenning provides education, not medical advice, diagnosis or treatment.